Carlo Conti

Consultant

Domaines d'activité:

Life Sciences et droit de la santé
Droit constitutionnel et administratif
Droit commercial et droit des sociétés

Autres activités:

Divers mandats dans les conseils d'administration de différentes entreprises en tant que président ou membre
Président ou membre de la direction de diverses organisations

Parcours professionnel:

2023	Consultant chez Wenger Plattner
2016	Associé chez Wenger Plattner
2014	Consultant chez Wenger Plattner
2000	Conseiller d'Etat du canton de Bâle-Ville, directeur du département de la santé
1985	F. Hoffmann-La Roche SA, fonction dirigeante au sein du service juridique et relations publiques
1985	Université de Bâle (Dr. iur.)
1982	Avocat
1978	Université de Bâle (lic. iur.)

Publications choisies:

Digital Health Laws and Regulations Switzerland 2024
In: The International Comparative Legal Guides (ICLG), Fifth Edition, London 2024, p. 205-213

Drug & Medical Device Litigation 2023 - Practical cross-border insights into drug and medical device litigation
In: The International Comparative Legal Guides (ICLG), Fourth Edition, London 2023, p. 135-142

GLI - Pricing & Reimbursement 2022
GLI - Pricing & Reimbursement 2022, Fifth Edition, p. 218 - 227

Kommentar zu Art. 16a - 16c HMG
In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

GLI - Pricing & Reimbursement 2021
GLI – Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204

GLI - Pricing & Reimbursement 2020
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.

The Pharma Legal Handbook Switzerland
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms | Pharma Board Room, London 2020

GLI - Pricing & Reimbursement 2019
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and has to satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.

GLI – Pricing & Reimbursement 2018
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are in principle granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare.

Versorgungsmanagement im Spannungsfeld zwischen Daten-, Patientenschutz und sektoralen Versorgungsgrenzen
In: Versorgungsmanagement in Gesundheitssystemen, Rebscher Herbert / Kaufmann Stefan (Hrsg.), Heidelberg 2013, S. 139 ff.